KBC Group
PTCT icon

KBC Group’s PTC Therapeutics PTCT Stock Holding History

KBC Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$152K Hold
2,347
– – ﹤0.01% 1145
2026
Q2 		$191K Hold
2,347
– – ﹤0.01% 1066
2026
Q1 		$160K Hold
2,347
– – ﹤0.01% 1063
2025
Q4 		$178K Hold
2,347
– – ﹤0.01% 965
2025
Q3 		$144K Hold
2,347
– – ﹤0.01% 1058
2025
Q2 		$115K Sell
2,347
-724
-24% -$34.4K ﹤0.01% 1115
2025
Q1 		$156K Buy
3,071
+26
+0.9% +$1.3K ﹤0.01% 1217
2024
Q4 		$137K Buy
3,045
+813
+36% +$34.8K ﹤0.01% 1350
2024
Q3 		$83K Buy
2,232
+504
+29% +$16.9K ﹤0.01% 1416
2024
Q2 		$53K Sell
1,728
-442
-20% -$14.3K ﹤0.01% 1583
2024
Q1 		$63K Buy
2,170
+619
+40% +$17.3K ﹤0.01% 1410
2023
Q4 		$43K Hold
1,551
– – ﹤0.01% 1634
2023
Q3 		$35K Buy
+1,551
New +$57.7K ﹤0.01% 1714

Other funds holding PTCT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $33.9B AUM 47.7% 1-Year Est. Return

KBC Group's PTCT Position: Q3 2026 in Review

KBC Group held its PTC Therapeutics (PTCT) position steady in Q3 2026 at 2,347 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.

KBC Group first reported a position in PTCT in Q3 2023 and has held it in 13 quarters since. The position peaked at $191K in Q2 2026. 275 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • KBC Group held 2,347 shares of PTC Therapeutics worth $152K as of Q3 2026.
  • KBC Group left its PTC Therapeutics share count unchanged in Q3 2026.
  • PTC Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1145 holding.
  • KBC Group first reported a position in PTC Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • KBC Group's PTC Therapeutics position peaked at $191K in Q2 2026.
  • 275 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.